Furthermore, we argue that inhibition of JAK-STAT signaling might sensitize B-cell lymphoma cells towards macrophage mediated ADCP and JAK2 inhibitors should be evaluated and utilized in future treatment concepts of B-cell malignancies. The gene discussed is JAK2; the disease is B-cell non-Hodgkin lymphoma.